Developed
with the aim to ensure the improved screening of drug candidates earlier on in
the development process, Molecular Profiles and GEA Process Engineering are
working to develop a unique way of preparing solid dispersions of drugs and
polymers. The purpose is to understand
the viability of the potential drug delivery platform at single particle scale
by comparing with batch produced spray dried approaches. GEA Process
Engineering is the world leader in process engineering, process equipment and
plant engineering, specialising in the manufacture of products in powder,
granular or agglomerate form in the food, chemical and pharmaceutical
industries. With 79 years experience in supplying spray drying solutions to the
pharmaceutical industry, the Danish-based company has gained a wealth of data
in this industry. The benefits of using the GEA Niro technology for this
application are the ability to assess the stability of drugs in polymer systems
where only an extremely limited amount of API is available and where multiple
polymer types/drug loadings are required to be screened for developability.
Claire
Madden-Smith at Molecular Profiles comments “We are pleased to have partnered with
GEA Process Engineering on this project which enables us to collaboratively
bring an innovative research approach to formulation development”.
Jesper
Jensen, Research Engineer, GEA Process Engineering comments “The combined
efforts of GEA Process Engineering and Molecular Profiles will rigorously test
new approaches in spray drying formulations and we’re looking forward to be
able to offer improved processes and efficiencies for formulation
development”.
The
collaboration highlights Molecular Profiles’ ability to characterise the
physicochemical properties of ‘single’ particle spray dried materials and
compare with conventional spray dried material prepared at bulk scale. Griseofulvin-PEG6000
solid dispersion samples at 2.5 % and 20 % loading are analysed using X-ray
Photoelectron Spectroscopy (XPS), Atomic Force Microscopy (AFM), confocal Raman
microscopy, FT Raman/FTIR, powder X-ray diffraction (PXRD), differential
scanning calorimetry (DSC) and scanning electron microscopy (SEM) to compare
surface vs. bulk properties and determine equivalence of the materials produced
using the two processes.
More
information about Molecular Profiles’ award-winning services is available at
www.molprofiles.co.uk, by e-mail at info@molprofiles.co.uk or call Andrew
Parker on +44 115 8718888.
About Molecular Profiles
Molecular
Profiles was founded in 1997 by a group of pharmaceutical scientists
specialising in advanced characterisation of pharmaceutical and biological
materials. Since then, the company has achieved a unique global position in
pharmaceutical R&D and has developed a wide portfolio of pharmaceutical
development services including formulation & analytical development and
clinical trial manufacturing up to and including Phase II. The company is
ideally placed to offer its clients a range of targeted solutions to help them
to overcome the most challenging issues in drug development. Molecular
Profiles’ contribution to the industry was acknowledged in 2007 and 2011 by the
receipt of the Queens Award for Enterprise in the innovation category, the most
prestigious business honour achievable in the UK.
For further
press information please contact: Celine Goodier, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel,
Cheshire, CW4 8AA, United Kingdom.
Tel: + 44 1477 539 539 Fax: +44
1477 539 540 E-mail: molecular@scottpr.com.
